TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00731185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray
Description: MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00590551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sling or no sling
Description: Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
Study: NCT04364594

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: conjunctival swab
Description: analysis of conjunctival cells (real time PCR) collected by conjunctival swabs in both eyes
Study: NCT00430872

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Survey about the severity of certain symptoms lasting 10-15 minutes.
Study: NCT01395758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197 plus erlotinib
Description: Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed, docetaxel or gemcitabine
Description: Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
Study: NCT04141865

Intervention type: DEVICE
Intervention: Xen
Description: Xen microstent implantation

Intervention type: DEVICE
Intervention: Aqueous shunt
Description: Aqueous shunt implantation
Study: NCT03571711

Intervention type: DRUG
Intervention: Meropenem Injection
Description: Meropenem is administered as prescribed by treating physician
Study: NCT02128282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study: NCT02794480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSK MDI
Description: It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSK MDI
Description: It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AZ MDI
Description: It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AZ MDI
Description: It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
Study: NCT02796391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) Cigarettes
Description: Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) Cigarettes
Description: Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) Cigarettes
Description: Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) Cigarettes
Description: Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm.
Study: NCT01926860

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Study: NCT04088266

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 16 mg buprenorphine with 4 mg naloxone sublingual film
Description: CASSIPA®
Study: NCT00978913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: DC vaccination, one vaccine biweekly
Study: NCT02796391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) Cigarettes
Description: Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm.
Study: NCT04446988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint injection
Description: Injection of sacroiliac joint with local anesthetic and steroid
Study: NCT02796391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) Cigarettes
Description: Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One on One Counseling
Description: All participants will receive One on One Counseling.
Study: NCT00834899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
Study: NCT02724202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
Study: NCT00628485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION
Description: The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION
Description: The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BION
Description: A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
Study: NCT02724202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-flurorouracil
Description: Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
Study: NCT01625013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc-One (G-F 20)
Description: Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
Study: NCT01582204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124IcG250
Description: Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
Study: NCT03197454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Forty-two minutes of training on computerized, casual video games.
Study: NCT01685593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal binder

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no binder
Study: NCT00805389

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B™
Description: 2 doses intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fendrix™
Description: 2 doses intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hepatitis B vaccines (GSK223192A)
Description: 2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hepatitis B vaccines (GSK223192A)
Description: 2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hepatitis B vaccines (GSK223192A)
Description: 2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBsAg (Booster injection)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBsAg (Booster injection)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBsAg (Booster injection)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBsAg (Booster injection)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBsAg (Booster injection)
Description: Single dose intramuscular injection
Study: NCT00152126

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: Autologous stem cell transplantation
Study: NCT00262730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Description: 20 mcg/kg 3x each week (Maintenance cycles)
Study: NCT02796391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One on One Counseling
Description: All participants will receive One on One Counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One on One Counseling
Description: All participants will receive One on One Counseling.
Study: NCT00262730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
Study: NCT02796391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One on One Counseling
Description: All participants will receive One on One Counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One on One Counseling
Description: All participants will receive One on One Counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One on One Counseling
Description: All participants will receive One on One Counseling.
Study: NCT00262730

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: RT: 60 Gy (6 weeks) concomitant therapy
Study: NCT02570542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Study: NCT00644254

Intervention type: PROCEDURE
Intervention: Pancreatic resection
Description: PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
Study: NCT03089216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Bleaching(2x20)
Description: one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Bleaching(2x20) with arginine
Description: one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Bleaching (1x20)
Description: one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Bleaching(1x20) with arginine
Description: one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% arginine and calcium carbonate
Description: using during all the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% arginine and calcium carbonate
Description: using during all the treatment.
Study: NCT03916172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Open Door Approach to Parenting Teenagers (APT)
Description: APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
Study: NCT02054143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial pressure of CO2 at the end of an exhaled breath
Description: Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
Study: NCT02570542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor
Description: Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine, etoposide, cytarabine, melphalan
Description: Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine, etoposide, cytarabine, melphalan
Description: Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Study: NCT02240550

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor Hernia Repair System
Description: The 3-D hernia mesh will be used in the repair of your inguinal hernia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein hernia repair
Description: The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
Study: NCT03848234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 2 trans dermal patches to be changed twice a week for the duration of 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol
Description: 2 trans dermal patches to be changed twice a week for the duration of 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 trans dermal patches to be changed twice a week for the duration of 8 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
Study: NCT00687622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
Study: NCT00736853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride Plus Acetaminophen (Open-Label)
Description: Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)
Description: Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Double-Blind)
Description: Matching placebo will be given up to 4 weeks.